GLP-1 microdosers are chasing longevity

GLP-1 microdosers are chasing longevity Skip to content Subscribe today Every print subscription comes with full digital access Subscribe Now Menu All Topics Health Humans Anthropology Health & Medicine Archaeology Psychology View All Life Animals Plants Ecosystems Paleontology Neuroscience Genetics Microbes View All Earth Agriculture Climate Oceans Environment View All Physics Materials Science Quantum Physics Particle Physics View All Space Astronomy Planetary Science Cosmology View All Magazine Menu All Stories Multimedia Reviews Puzzles Collections Educator Portal Century of Science Unsung characters Coronavirus Outbreak Newsletters Investors Lab About SN Explores Our Store SIGN IN Donate Home INDEPENDENT JOURNALISM SINCE 1921 SIGN IN Search Open search Close search Home INDEPENDENT JOURNALISM SINCE 1921 All Topics Earth Agriculture Climate Oceans Environment Humans Anthropology Health & Medicine Archaeology Psychology Life Animals Plants Ecosystems Paleontology Neuroscience Genetics Microbes Physics Materials Science Quantum Physics Particle Physics Space Astronomy Planetary Science Cosmology Tech Computing Artificial Intelligence Chemistry Math Science & Society All Topics Health Humans Humans Anthropology Health & Medicine Archaeology Psychology Recent posts in Humans Health & Medicine GLP-1 microdosers are chasing longevity By Jamie Ducharme4 hours ago Archaeology A new study questions when people first reached South America By Tom Metcalfe23 hours ago Health & Medicine Are pig organs the future of transplantation? By Meghan RosenMarch 17, 2026 Life Life Animals Plants Ecosystems Paleontology Neuroscience Genetics Microbes Recent posts in Life Plants Check out 6 ways orchids use tricks to reproduce By Mandana Tadayon45 minutes ago Animals Mosquitoes get the ‘I’m full’ signal from their butts, not their brains By Jake Buehler2 hours ago Microbes How warming is shifting microbial worlds By Erin Garcia de JesúsMarch 19, 2026 Earth Earth Agriculture Climate Oceans Environment Recent posts in Earth Earth Earth’s continental plates were moving 3.48 billion years ago By Douglas Fox23 hours ago Microbes How warming is shifting microbial worlds By Erin Garcia de JesúsMarch 19, 2026 Earth To make a ‘Snowball Earth,’ sci-fi moves fast. Geology is far slower By Carolyn GramlingMarch 18, 2026 Physics Physics Materials Science Quantum Physics Particle Physics Recent posts in Physics Physics A static electricity mystery comes to the surface By Emily ConoverMarch 18, 2026 Plants Tree tops sparkle with electricity during thunderstorms By Lily BurtonMarch 10, 2026 Physics When the pressure’s off, this superconductor appears to break records By Emily ConoverMarch 9, 2026 Space Space Astronomy Planetary Science Cosmology Recent posts in Space Space One possible recipe for life on Titan is a bust By Tina Hesman SaeyMarch 11, 2026 Astronomy A strange ‘chirp’ in a brilliant stellar blast points to a magnetar By Jay BennettMarch 11, 2026 Planetary Science NASA’s DART spacecraft changed an asteroid’s orbit around the sun By Lisa GrossmanMarch 6, 2026 Column Health & Medicine GLP-1 microdosers are chasing longevity Research hasn’t yet caught up to the hype By Jamie Ducharme 4 hours ago GLP-1 medications hold lots of promise for diverse areas of health, but any broad benefits of microdosing are still unknown. Stefania Pelfini la Waziya/Moment/Getty Images Share this:Share Share via email (Opens in new window) Email Share on Facebook (Opens in new window) Facebook Share on Reddit (Opens in new window) Reddit Share on X (Opens in new window) X Print (Opens in new window) Print More than 10 percent of U.S. adults take GLP-1 drugs. But not all of them are taking full doses. Around one in seven users has “microdosed” injections, a recent survey by the health tracking app Evidation found. Some take tiny portions for practical reasons, such as cutting costs. Others have loftier ambitions: They hope to harness the drugs’ powerful effects to achieve better health and longer lives without losing a lot of weight or experiencing side effects such as GI issues and muscle loss. Medications such as Ozempic and Wegovy mimic the body’s GLP-1 hormone, which helps regulate appetite, metabolism and blood sugar. That has made the drugs blockbuster treatments for type 2 diabetes and obesity. But to date, “there is no rigorous scientific data to support microdosing,” says bariatric medicine specialist Katy Williams of the University of Missouri Health Care in Jefferson City. Sign up for our newsletter We summarize the week's scientific breakthroughs every Thursday. That hasn’t stopped some intrepid biohackers from trying it, though. Companies like AgelessRx, a longevity-focused telehealth clinic, explicitly sell GLP-1 microdoses for this purpose, advertising them as “a powerful new path to promoting long-term wellness.” There is some research to suggest GLP-1s can promote healthy aging by improving overall health. The drugs have been found to reduce inflammation and oxidative stress, lower risks of major cardiovascular problems, lower cancer risk and more. Such findings have prompted scientists to study the drugs as potential treatments for illnesses as diverse as Alzheimer’s disease and arthritis. Some experts have even wondered whether the drugs’ systemic effects might slow cellular aging and prevent age-related chronic conditions, potentially making them the first true longevity drugs to hit the market. But science hasn’t caught up to the hype. There’s scant published research on GLP-1 microdosing, although some teams are studying it. For instance, a low dose of the active ingredient in Ozempic and Wegovy might reduce alcohol cravings, researchers reported last year in JAMA Psychiatry. And AgelessRx is starting a clinical trial focused on how GLP-1 microdosing affects health and quality of life. Some people aren’t waiting around for data. That includes many patients of Shamsah Amersi, an ob-gyn in Santa Monica, Calif. Amersi discusses microdosing with all patients entering perimenopause, she says, and about 60 percent of her patients over 40 use one. Amersi claims that the majority of microdosers under her care feel better and see improvements on lab tests measuring metabolic and overall health. “GLP-1 is one of the most transformative therapies in modern medicine,” she says, though she notes the drugs are not for everyone. Amersi thinks patients can benefit from microdosing now, even without data to prove its efficacy, if they work with a doctor to carefully monitor their response. Other experts remain wary. There isn’t enough data to confirm that microdosing can help you live longer, says clinical pharmacist practitioner Anne Komé of the University of North Carolina Medical Center in Chapel Hill, who published a 2025 e-letter about microdosing GLP-1s in Diabetes Care. But it could help clinicians optimize therapy